Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
CTI BioPharma
Study ID
NCT01773187
Phase
PHASE3
Status
Terminated

Conditions

  • Post-essential Thrombocythemia Myelofibrosis
  • Post-polycythemia Vera Myelofibrosis
  • Primary Myelofibrosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pacritinib — DRUG
  • Best Available Therapy — DRUG

Study Details

Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with primary or secondary myelofibrosis.

Key Dates

Start date
Jan 31, 2013
Status verified
Sep 2020
Primary completion
Jan 31, 2015
Completion
Apr 30, 2016

Study Design

Enrollment
327 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Pacritinib
    Pacritinib 400 mg QD
  • Active Comparator: Best Available Therapy
    BAT includes any physician-selected treatment for primary or secondary myelofibrosis with the exclusion of JAK inhibitors (inhibitors of Janus kinases)

Primary Outcome Measure

Spleen Volume Reduction [ Time Frame: Baseline to Week 24 ]

Locations (4)

FacilityCityStateZIPSite coordinators
CTI Investigational Site 10002ScottsdaleArizona85259-
CTI Investigational Site 10004OmahaNebraska68198-
CTI Investigational Site 10001MorristownNew Jersey07962-
CTI Investigational Site 10003GreenvilleSouth Carolina29601-

Find similar trials in Scottsdale, AZ

By research site
CTI Investigational· Scottsdale, AZCTI Investigational· Omaha, NECTI Investigational· Morristown, NJCTI Investigational· Greenville, SC

Related Studies